Drugs / PRT-064040
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07016516 | Jun → Sep 2025 | migraine disorder | Sichuan Purity Pharmaceutical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07304518 | Jan → Sep 2026 overdue | migraine disorder | Sichuan Purity Pharmaceutical Technology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRT-064040 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07304518 ↗ |
| Route | Intranasal | “PRT-064040 nasal spray” NCT07016516 ↗ |